drugset
drugset / Trial / NCT05920941

Mass Balance Study of [14C]JAB-21822

NCT05920941 ↗

Phase 1 Completed 6 enrolled Allist Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

Mass Balance Study of \[14C\]JAB-21822 in China Healthy Subjects

Timeline

Start
2023-07-08
Primary completion
2023-08-09
Completion
2023-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Glecirasib Small molecule 800 mg Oral

Indications

No indication recorded.